APLS
Apellis Pharmaceuticals, Inc.$41.03+0.00 (—)Prev Close$41.06·MCap$5.25B·P/E45.09·Vol—·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
55
$6.46M
◆
Net Activity
Net Seller
$6.46M
●
Active Insiders
9
last 12 mo
Over the past 12 months, insider activity at Apellis Pharmaceuticals, Inc. (APLS) has been exclusively selling, with 0 insider purchases totaling $0.00 and 55 insider sales totaling $6.46M. The most recent insider transaction was by DeLong Mark Jeffrey (officer: Chief Business & Strat Officer), who sold $8.2K worth of shares on Feb 13, 2026. Apellis Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $5.25B.
APLS Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | DeLong Mark Jeffrey | officer: Chief Business & Strat Officer | Sell | 368 | $22.15 | $8.2K | 114,591 |
| Feb 11, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | 368 | $22.15 | $8.2K | 0 |
| Jan 23, 2026 | Baumal Caroline | officer: Chief Medical Officer | Sell | 2,797 | $21.77 | $60.9K | 86,527 |
| Jan 23, 2026 | Chopas James George | officer: VP/Chief Accounting Officer | Sell | 2,064 | $21.77 | $44.9K | 49,805 |
| Jan 23, 2026 | DeLong Mark Jeffrey | officer: Chief Business & Strat Officer | Sell | 3,371 | $21.77 | $73.4K | 78,353 |
| Jan 23, 2026 | Deschatelets Pascal | officer: Chief Scientific Officer | Sell | 5,928 | $21.77 | $129.0K | 1,151,382 |
| Jan 23, 2026 | Francois Cedric | director, officer: Chief Executive Officer | Sell | 27,192 | $21.77 | $591.8K | 286,045 |
| Jan 23, 2026 | Nicholson Nur | officer: Chief Technical Officer | Sell | 7,725 | $21.77 | $168.1K | 71,118 |
| Jan 23, 2026 | Sullivan Timothy Eugene | officer: Chief Financial Officer | Sell | 10,287 | $21.77 | $223.9K | 93,901 |
| Jan 23, 2026 | Watson David O. | officer: General Counsel | Sell | 7,832 | $21.77 | $170.5K | 88,531 |
| Jan 22, 2026 | Baumal Caroline | Chief Medical Officer | Sell | 2,797 | $21.77 | $60.9K | 0 |
| Jan 22, 2026 | Chopas James George | VP/Chief Accounting Officer | Sell | 2,064 | $21.77 | $44.9K | 0 |
| Jan 22, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | 3,371 | $21.77 | $73.4K | 0 |
| Jan 22, 2026 | Deschatelets Pascal | Chief Scientific Officer | Sell | 5,928 | $21.77 | $129.0K | 0 |
| Jan 22, 2026 | Francois Cedric | Chief Executive Officer | Sell | 27,192 | $21.77 | $591.8K | 0 |
| Jan 22, 2026 | Nicholson Nur | Chief Technical Officer | Sell | 7,725 | $21.77 | $168.1K | 0 |
| Jan 22, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | Sell | 10,287 | $21.77 | $223.9K | 0 |
| Jan 22, 2026 | Watson David O. | General Counsel | Sell | 7,832 | $21.77 | $170.5K | 0 |
| Jan 21, 2026 | Baumal Caroline | officer: Chief Medical Officer | Sell | 1,882 | $19.79 | $37.3K | 89,324 |
| Jan 21, 2026 | Chopas James George | officer: VP/Chief Accounting Officer | Sell | 726 | $19.79 | $14.4K | 51,869 |
| Jan 21, 2026 | DeLong Mark Jeffrey | officer: Chief Business & Strat Officer | Sell | 1,334 | $19.79 | $26.4K | 81,724 |
| Jan 21, 2026 | Deschatelets Pascal | officer: Chief Scientific Officer | Sell | 909 | $19.79 | $18.0K | 1,157,310 |
| Jan 21, 2026 | Francois Cedric | director, officer: Chief Executive Officer | Sell | 8,182 | $19.79 | $161.9K | 313,237 |
| Jan 21, 2026 | Nicholson Nur | officer: Chief Technical Officer | Sell | 2,203 | $19.79 | $43.6K | 78,843 |
| Jan 21, 2026 | Sullivan Timothy Eugene | officer: Chief Financial Officer | Sell | 2,892 | $19.79 | $57.2K | 104,188 |
| Jan 21, 2026 | Watson David O. | officer: General Counsel | Sell | 2,475 | $19.79 | $49.0K | 96,363 |
| Jan 20, 2026 | Baumal Caroline | Chief Medical Officer | Sell | 1,882 | $19.79 | $37.3K | 0 |
| Jan 20, 2026 | Chopas James George | VP/Chief Accounting Officer | Sell | 726 | $19.79 | $14.4K | 0 |
| Jan 20, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | 1,334 | $19.79 | $26.4K | 0 |
| Jan 20, 2026 | Deschatelets Pascal | Chief Scientific Officer | Sell | 909 | $19.79 | $18.0K | 0 |
| Jan 20, 2026 | Francois Cedric | Chief Executive Officer | Sell | 8,182 | $19.79 | $161.9K | 0 |
| Jan 20, 2026 | Nicholson Nur | Chief Technical Officer | Sell | 2,203 | $19.79 | $43.6K | 0 |
| Jan 20, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | Sell | 2,892 | $19.79 | $57.2K | 0 |
| Jan 20, 2026 | Watson David O. | General Counsel | Sell | 2,475 | $19.79 | $49.0K | 0 |
| Jan 15, 2026 | Chopas James George | officer: VP/Chief Accounting Officer | Sell | 873 | $22.19 | $19.4K | 52,595 |
| Jan 15, 2026 | DeLong Mark Jeffrey | officer: Chief Business & Strat Officer | Sell | 1,780 | $22.19 | $39.5K | 83,058 |
| Jan 15, 2026 | Deschatelets Pascal | officer: Chief Scientific Officer | Sell | 2,277 | $22.19 | $50.5K | 1,158,219 |
| Jan 15, 2026 | Francois Cedric | director, officer: Chief Executive Officer | Sell | 10,186 | $22.19 | $226.0K | 321,419 |
| Jan 15, 2026 | Nicholson Nur | officer: Chief Technical Officer | Sell | 2,618 | $22.19 | $58.1K | 81,046 |
| Jan 15, 2026 | Sullivan Timothy Eugene | officer: Chief Financial Officer | Sell | 3,856 | $22.19 | $85.6K | 107,080 |
| Jan 15, 2026 | Watson David O. | officer: General Counsel | Sell | 5,780 | $22.19 | $128.2K | 98,838 |
| Jan 13, 2026 | Chopas James George | VP/Chief Accounting Officer | Sell | 873 | $22.19 | $19.4K | 0 |
| Jan 13, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | 1,780 | $22.19 | $39.5K | 0 |
| Jan 13, 2026 | Deschatelets Pascal | Chief Scientific Officer | Sell | 2,277 | $22.19 | $50.5K | 0 |
| Jan 13, 2026 | Francois Cedric | Chief Executive Officer | Sell | 10,186 | $22.19 | $226.0K | 0 |
| Jan 13, 2026 | Nicholson Nur | Chief Technical Officer | Sell | 2,618 | $22.19 | $58.1K | 0 |
| Jan 13, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | Sell | 3,856 | $22.19 | $85.6K | 0 |
| Jan 13, 2026 | Watson David O. | General Counsel | Sell | 5,780 | $22.19 | $128.2K | 0 |
| Jan 6, 2026 | Baumal Caroline | officer: Chief Medical Officer | Sell | 3,020 | $25.53 | $77.1K | 91,206 |
| Jan 5, 2026 | Baumal Caroline | Chief Medical Officer | Sell | 3,020 | $25.53 | $77.1K | 0 |
Showing 1–50 of 380
1 / 8
...
APLS Insider Buying Activity
The following table shows recent insider purchases of Apellis Pharmaceuticals, Inc. (APLS) stock reported via SEC Form 4 filings.
No insider buying activity found for APLS in the last 12 months.
APLS Insider Selling Activity
The following table shows recent insider sales of Apellis Pharmaceuticals, Inc. (APLS) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 13, 2026 | DeLong Mark Jeffrey | officer: Chief Business & Strat Officer | Sell | 368 | $22.15 | $8.2K | 114,591 |
| Feb 11, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | 368 | $22.15 | $8.2K | 0 |
| Jan 23, 2026 | Baumal Caroline | officer: Chief Medical Officer | Sell | 2,797 | $21.77 | $60.9K | 86,527 |
| Jan 23, 2026 | Chopas James George | officer: VP/Chief Accounting Officer | Sell | 2,064 | $21.77 | $44.9K | 49,805 |
| Jan 23, 2026 | DeLong Mark Jeffrey | officer: Chief Business & Strat Officer | Sell | 3,371 | $21.77 | $73.4K | 78,353 |
| Jan 23, 2026 | Deschatelets Pascal | officer: Chief Scientific Officer | Sell | 5,928 | $21.77 | $129.0K | 1,151,382 |
| Jan 23, 2026 | Francois Cedric | director, officer: Chief Executive Officer | Sell | 27,192 | $21.77 | $591.8K | 286,045 |
| Jan 23, 2026 | Nicholson Nur | officer: Chief Technical Officer | Sell | 7,725 | $21.77 | $168.1K | 71,118 |
| Jan 23, 2026 | Sullivan Timothy Eugene | officer: Chief Financial Officer | Sell | 10,287 | $21.77 | $223.9K | 93,901 |
| Jan 23, 2026 | Watson David O. | officer: General Counsel | Sell | 7,832 | $21.77 | $170.5K | 88,531 |
| Jan 22, 2026 | Baumal Caroline | Chief Medical Officer | Sell | 2,797 | $21.77 | $60.9K | 0 |
| Jan 22, 2026 | Chopas James George | VP/Chief Accounting Officer | Sell | 2,064 | $21.77 | $44.9K | 0 |
| Jan 22, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | 3,371 | $21.77 | $73.4K | 0 |
| Jan 22, 2026 | Deschatelets Pascal | Chief Scientific Officer | Sell | 5,928 | $21.77 | $129.0K | 0 |
| Jan 22, 2026 | Francois Cedric | Chief Executive Officer | Sell | 27,192 | $21.77 | $591.8K | 0 |
| Jan 22, 2026 | Nicholson Nur | Chief Technical Officer | Sell | 7,725 | $21.77 | $168.1K | 0 |
| Jan 22, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | Sell | 10,287 | $21.77 | $223.9K | 0 |
| Jan 22, 2026 | Watson David O. | General Counsel | Sell | 7,832 | $21.77 | $170.5K | 0 |
| Jan 21, 2026 | Baumal Caroline | officer: Chief Medical Officer | Sell | 1,882 | $19.79 | $37.3K | 89,324 |
| Jan 21, 2026 | Chopas James George | officer: VP/Chief Accounting Officer | Sell | 726 | $19.79 | $14.4K | 51,869 |
| Jan 21, 2026 | DeLong Mark Jeffrey | officer: Chief Business & Strat Officer | Sell | 1,334 | $19.79 | $26.4K | 81,724 |
| Jan 21, 2026 | Deschatelets Pascal | officer: Chief Scientific Officer | Sell | 909 | $19.79 | $18.0K | 1,157,310 |
| Jan 21, 2026 | Francois Cedric | director, officer: Chief Executive Officer | Sell | 8,182 | $19.79 | $161.9K | 313,237 |
| Jan 21, 2026 | Nicholson Nur | officer: Chief Technical Officer | Sell | 2,203 | $19.79 | $43.6K | 78,843 |
| Jan 21, 2026 | Sullivan Timothy Eugene | officer: Chief Financial Officer | Sell | 2,892 | $19.79 | $57.2K | 104,188 |
| Jan 21, 2026 | Watson David O. | officer: General Counsel | Sell | 2,475 | $19.79 | $49.0K | 96,363 |
| Jan 20, 2026 | Baumal Caroline | Chief Medical Officer | Sell | 1,882 | $19.79 | $37.3K | 0 |
| Jan 20, 2026 | Chopas James George | VP/Chief Accounting Officer | Sell | 726 | $19.79 | $14.4K | 0 |
| Jan 20, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | 1,334 | $19.79 | $26.4K | 0 |
| Jan 20, 2026 | Deschatelets Pascal | Chief Scientific Officer | Sell | 909 | $19.79 | $18.0K | 0 |
| Jan 20, 2026 | Francois Cedric | Chief Executive Officer | Sell | 8,182 | $19.79 | $161.9K | 0 |
| Jan 20, 2026 | Nicholson Nur | Chief Technical Officer | Sell | 2,203 | $19.79 | $43.6K | 0 |
| Jan 20, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | Sell | 2,892 | $19.79 | $57.2K | 0 |
| Jan 20, 2026 | Watson David O. | General Counsel | Sell | 2,475 | $19.79 | $49.0K | 0 |
| Jan 15, 2026 | Chopas James George | officer: VP/Chief Accounting Officer | Sell | 873 | $22.19 | $19.4K | 52,595 |
| Jan 15, 2026 | DeLong Mark Jeffrey | officer: Chief Business & Strat Officer | Sell | 1,780 | $22.19 | $39.5K | 83,058 |
| Jan 15, 2026 | Deschatelets Pascal | officer: Chief Scientific Officer | Sell | 2,277 | $22.19 | $50.5K | 1,158,219 |
| Jan 15, 2026 | Francois Cedric | director, officer: Chief Executive Officer | Sell | 10,186 | $22.19 | $226.0K | 321,419 |
| Jan 15, 2026 | Nicholson Nur | officer: Chief Technical Officer | Sell | 2,618 | $22.19 | $58.1K | 81,046 |
| Jan 15, 2026 | Sullivan Timothy Eugene | officer: Chief Financial Officer | Sell | 3,856 | $22.19 | $85.6K | 107,080 |
| Jan 15, 2026 | Watson David O. | officer: General Counsel | Sell | 5,780 | $22.19 | $128.2K | 98,838 |
| Jan 13, 2026 | Chopas James George | VP/Chief Accounting Officer | Sell | 873 | $22.19 | $19.4K | 0 |
| Jan 13, 2026 | DeLong Mark Jeffrey | Chief Business & Strat Officer | Sell | 1,780 | $22.19 | $39.5K | 0 |
| Jan 13, 2026 | Deschatelets Pascal | Chief Scientific Officer | Sell | 2,277 | $22.19 | $50.5K | 0 |
| Jan 13, 2026 | Francois Cedric | Chief Executive Officer | Sell | 10,186 | $22.19 | $226.0K | 0 |
| Jan 13, 2026 | Nicholson Nur | Chief Technical Officer | Sell | 2,618 | $22.19 | $58.1K | 0 |
| Jan 13, 2026 | Sullivan Timothy Eugene | Chief Financial Officer | Sell | 3,856 | $22.19 | $85.6K | 0 |
| Jan 13, 2026 | Watson David O. | General Counsel | Sell | 5,780 | $22.19 | $128.2K | 0 |
| Jan 6, 2026 | Baumal Caroline | officer: Chief Medical Officer | Sell | 3,020 | $25.53 | $77.1K | 91,206 |
| Jan 5, 2026 | Baumal Caroline | Chief Medical Officer | Sell | 3,020 | $25.53 | $77.1K | 0 |
APLS Insiders
Similar Stocks to APLS
VRTX
Vertex Pharmaceuticals Incorporated
$518.23+1.50%
$131.05B
REGN
Regeneron Pharmaceuticals, Inc.
$799.18+0.13%
$81.33B
MRNA
Moderna, Inc.
$180.77+4.47%
$61.12B
RVMD
Revolution Medicines, Inc.
$194.15+0.67%
$41.87B
INSM
Insmed Incorporated
$120.39-0.59%
$26.01B
INCY
Incyte Corporation
$125.75+0.87%
$25.40B
UTHR
United Therapeutics Corporation
$494.09+0.20%
$21.00B
NBIX
Neurocrine Biosciences, Inc.
$143.10-0.66%
$14.70B